Herombopag tablets + Herombopag placebo tablets

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Conditions

Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Trial Timeline

Jul 31, 2024 → Dec 1, 2025

NCT ID

NCT06507436

About Herombopag tablets + Herombopag placebo tablets

Herombopag tablets + Herombopag placebo tablets is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06507436. Target conditions include Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06507436	Phase 3	Recruiting	Jul 31, 2024	Dec 1, 2025	Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Competing Products

20 competing products in Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Placebo	Eli Lilly	Phase 1/2	41
Anti-(integrin beta-3) human monoclonal antibody	Rallybio	Phase 2	44
Placebo + Lusutrombopag	Shionogi	Phase 2	52
Lusutrombopag	Shionogi	Phase 2	52
Avatrombopag + Avatrombopag + Placebo	Eisai	Phase 2	52
avatrombopag	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	77
avatrombopag + Placebo	Eisai	Phase 2	52
Avatrombopag + Placebo + Pegylated interferon (PEG-IFN) + Telaprevir + Ribavirin	Eisai	Phase 2	52
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)	Eisai	Phase 3	77
Avatrombopag + Placebo + Standard of care	Eisai	Phase 3	77
Romiplostim	Kyowa Kirin	Phase 1/2	41
Romiplostim + Placebo	Kyowa Kirin	Phase 3	77
Romiplostim (AMG-531)	Kyowa Kirin	Phase 2	52
Romiplostim and danazol	Kyowa Kirin	Phase 2	52
ONO-7746	Ono Pharmaceutical	Phase 1	33
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1	33
Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved